CSU - ACAAI 2020 Knowledge Quiz

Q.1

Approximately how many patients with CSU are refractory to treatment with H1-antihistamines in the United States alone? *

Approximately 500,000
550,000 – 800,000
800,000 – 1.75 million
Approximately 2 million

The correct answer is 800,000 – 1.75 million patients.

Q.2

According to a presentation by Professor Sarbjit Saini, which of the following is not a positive predictor for omalizumab response. *

increased basophil FcεRI
negative BHRA
negative CD203
higher baseline IgE
positive autologous serum skin test (ASST+)

The correct answer is positive autologous serum skin test, which is considered a negative predictor of omalizumab response.

Q.3

What percentage of patients achieved complete disease control (UAS7=0) following their first dose of ligelizumab (72 mg) in a recent Phase IIb clinical trial? *

10.7%
18.1%
20.5%
21.2%

The correct answer is 20.5% as compared to 18.1% and 10.7% in the ligelizumab (240 mg) and omalizumab groups respectively.

Q.4

In patients with CSU, basopenia and eosinopenia are particularly useful biomarkers for… *

Disease activity
Disease duration
Autoimmunity
Treatment response to omalizumab
All of the above
None of the above

The correct answer is all of the above.

Q.5

International guidelines recommend against the long-term use of systemic corticosteroids in chronic urticaria. *

True
False

The correct answer is true, long-term use of glucocorticosteroids is not recommended to treat chronic urticaria.